

# Murray B Urowitz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1200276/publications.pdf>

Version: 2024-02-01

209  
papers

25,505  
citations

22153

59  
h-index

6836

155  
g-index

214  
all docs

214  
docs citations

214  
times ranked

14463  
citing authors

#	ARTICLE	IF	CITATIONS
1	Derivation of the sledai. A disease activity index for lupus patients. <i>Arthritis and Rheumatism</i> , 1992, 35, 630-640.	6.7	4,086
2	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 2677-2686.	6.7	3,838
3	The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1996, 39, 363-369.	6.7	2,042
4	Systemic lupus erythematosus disease activity index 2000. <i>Journal of Rheumatology</i> , 2002, 29, 288-91.	2.0	1,911
5	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1400-1412.	5.6	1,098
6	The bimodal mortality pattern of systemic lupus erythematosus. <i>American Journal of Medicine</i> , 1976, 60, 221-225.	1.5	911
7	Systemic lupus erythematosus. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16039.	30.5	816
8	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1151-1159.	0.9	759
9	The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index in patients with Systemic Lupus Erythematosus. <i>Arthritis and Rheumatism</i> , 1997, 40, 809-813.	6.7	586
10	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1706-1713.	0.9	391
11	The frequency and outcome of lupus nephritis: results from an international inception cohort study. <i>Rheumatology</i> , 2016, 55, 252-262.	1.9	370
12	Risk factors for coronary heart disease in women with systemic lupus erythematosus: The Toronto Risk Factor Study. <i>Arthritis and Rheumatism</i> , 2003, 48, 3159-3167.	6.7	327
13	Changing Patterns in Mortality and Disease Outcomes for Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2008, 35, 2152-2158.	2.0	274
14	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 554-561.	0.9	268
15	Cancer risk in systemic lupus: An updated international multi-centre cohort study. <i>Journal of Autoimmunity</i> , 2013, 42, 130-135.	6.5	249
16	The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2010, 62, 863-868.	6.7	245
17	Accrual of organ damage over time in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2003, 30, 1955-9.	2.0	218
18	Malignancy in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1996, 39, 1050-1054.	6.7	204

#	ARTICLE	IF	CITATIONS
19	Lupus retinopathy. <i>Arthritis and Rheumatism</i> , 1988, 31, 1105-1110.	6.7	203
20	PREMATURE ATHEROSCLEROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS. <i>Rheumatic Disease Clinics of North America</i> , 2000, 26, 257-278.	1.9	154
21	Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 543-546.	0.9	154
22	Serologically active clinically quiescent systemic lupus erythematosus. <i>American Journal of Medicine</i> , 1979, 66, 210-215.	1.5	151
23	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1502-1509.	0.9	143
24	Peripheral Neuropathy in Patients with Systemic Lupus Erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 203-211.	3.4	126
25	Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2009, 61, 1152-1158.	6.7	117
26	Lymphoma risk in systemic lupus: effects of disease activity versus treatment. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 138-142.	0.9	115
27	Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus. <i>Journal of Rheumatology</i> , 2003, 30, 1977-82.	2.0	115
28	Prolonged Serologically Active Clinically Quiescent Systemic Lupus Erythematosus: Frequency and Outcome. <i>Journal of Rheumatology</i> , 2010, 37, 1822-1827.	2.0	114
29	The 1000 Canadian Faces of Lupus: Determinants of Disease Outcome in a Large Multiethnic Cohort. <i>Journal of Rheumatology</i> , 2009, 36, 1200-1208.	2.0	111
30	Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1992, 35, 849-856.	6.7	107
31	The Early Protective Effect of Hydroxychloroquine on the Risk of Cumulative Damage in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2013, 40, 831-841.	2.0	105
32	Pregnancy Outcome Following First Trimester Exposure to Chloroquine. <i>American Journal of Perinatology</i> , 1991, 8, 174-178.	1.4	104
33	Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. <i>Journal of Rheumatology</i> , 2005, 32, 824-7.	2.0	103
34	Mycophenolate Mofetil for Induction Treatment of Lupus Nephritis: A Systematic Review and Metaanalysis. <i>Journal of Rheumatology</i> , 2011, 38, 69-78.	2.0	102
35	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 1837-1847.	5.6	98
36	Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1837-1844.	0.9	97

#	ARTICLE	IF	CITATIONS
37	Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. <i>Journal of Rheumatology</i> , 2007, 34, 70-5.	2.0	97
38	Prolonged Clinical Remission in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2014, 41, 1808-1816.	2.0	90
39	Prolonged remission in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2005, 32, 1467-72.	2.0	87
40	Headache in Systemic Lupus Erythematosus: Results From a Prospective, International Inception Cohort Study. <i>Arthritis and Rheumatism</i> , 2013, 65, 2887-2897.	6.7	84
41	Premature Atherosclerosis in Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2005, 31, 329-354.	1.9	82
42	All-cause, cause-specific and age-specific standardised mortality ratios of patients with systemic lupus erythematosus in Ontario, Canada over 43 years (1971â€“2013). <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 802-806.	0.9	80
43	Time to Recovery from Proteinuria in Patients with Lupus Nephritis Receiving Standard Treatment. <i>Journal of Rheumatology</i> , 2014, 41, 688-697.	2.0	79
44	Dyslipidemia in systemic lupus erythematosus: just another comorbidity?. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 604-610.	3.4	79
45	Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1308-1314.	0.9	78
46	Incidence rates of arterial and venous thrombosis after diagnosis of systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2005, 53, 609-612.	6.7	75
47	Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period. <i>Arthritis Care and Research</i> , 2012, 64, 511-518.	3.4	75
48	Cardiovascular and Pulmonary Manifestations of Systemic Lupus Erythematosus. <i>Current Rheumatology Reviews</i> , 2017, 13, 206-218.	0.8	75
49	The SLICC/ACR damage index: progress report and experience in the field. <i>Lupus</i> , 1999, 8, 632-637.	1.6	73
50	Kidney Biopsy in Systemic Lupus Erythematosus. II. Survival Analyses According to Biopsy Results. <i>Arthritis and Rheumatism</i> , 1991, 34, 1268-1273.	6.7	72
51	Development and Initial Validation of the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index 50. <i>Journal of Rheumatology</i> , 2011, 38, 275-284.	2.0	72
52	Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study. <i>Arthritis Research and Therapy</i> , 2011, 13, R156.	3.5	71
53	Defining Low Disease Activity in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2017, 69, 997-1003.	3.4	71
54	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1530-1536.	0.9	70

#	ARTICLE	IF	CITATIONS
55	Modified Framingham Risk Factor Score for Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2016, 43, 875-879.	2.0	70
56	Antinuclear Antibodyâ€“Negative Systemic Lupus Erythematosus in an International Inception Cohort. <i>Arthritis Care and Research</i> , 2019, 71, 893-902.	3.4	70
57	Optimal Monitoring For Coronary Heart Disease Risk in Patients with Systemic Lupus Erythematosus: A Systematic Review. <i>Journal of Rheumatology</i> , 2016, 43, 54-65.	2.0	67
58	Risk Factors for Development of Coronary Artery Disease in Women with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2009, 36, 2454-2461.	2.0	66
59	Kidney biopsy in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1994, 37, 559-567.	6.7	62
60	The significance of thrombocytopenia in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1983, 26, 1181-1186.	6.7	60
61	Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus. <i>Kidney International</i> , 2011, 79, 914-920.	5.2	60
62	Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 372-379.	0.9	59
63	Factors associated with refractory renal disease in patients with systemic lupus erythematosus: The role of patient nonadherence. <i>Arthritis and Rheumatism</i> , 2000, 13, 406-408.	6.7	56
64	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis Care and Research</i> , 2018, 70, 1478-1487.	3.4	55
65	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 281-289.	5.6	55
66	Contributions of Observational Cohort Studies in Systemic Lupus Erythematosus: The University of Toronto Lupus Clinic Experience. <i>Rheumatic Disease Clinics of North America</i> , 2005, 31, 211-221.	1.9	54
67	Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 634-640.	0.9	51
68	Evolution of Risk Factors for Atherosclerotic Cardiovascular Events in Systemic Lupus Erythematosus: A Longterm Prospective Study. <i>Journal of Rheumatology</i> , 2017, 44, 1841-1849.	2.0	49
69	Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. <i>Rheumatology</i> , 2021, 60, 5397-5407.	1.9	48
70	Ethnic variation in disease patterns and health outcomes in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2006, 33, 1990-5.	2.0	46
71	Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study. <i>Lupus Science and Medicine</i> , 2015, 2, e000104.	2.7	45
72	Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2018, 45, 1426-1439.	2.0	43

#	ARTICLE	IF	CITATIONS
73	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 370-378.	0.9	42
74	Do current arterial hypertension treatment guidelines apply to systemic lupus erythematosus patients? A critical appraisal. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 521-525.	3.4	41
75	The effect of menopause on disease activity in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2006, 33, 2192-8.	2.0	41
76	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. <i>Arthritis and Rheumatology</i> , 2016, 68, 1932-1944.	5.6	40
77	Association of systemic lupus erythematosus (SLE) genetic susceptibility loci with lupus nephritis in childhood-onset and adult-onset SLE. <i>Rheumatology</i> , 2020, 59, 90-98.	1.9	40
78	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 356-362.	0.9	40
79	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2020, 72, 67-77.	5.6	39
80	Interferon- $\gamma$ induces altered transitional B cell signaling and function in Systemic Lupus Erythematosus. <i>Journal of Autoimmunity</i> , 2015, 58, 100-110.	6.5	38
81	Anti-nucleosome antibodies outperform traditional biomarkers as longitudinal indicators of disease activity in systemic lupus erythematosus. <i>Rheumatology</i> , 2015, 54, 449-457.	1.9	37
82	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. <i>Rheumatology</i> , 2018, 57, 677-687.	1.9	37
83	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 775-781.	0.9	37
84	Myocardial Perfusion Imaging in Assessing Risk of Coronary Events in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2009, 36, 288-294.	2.0	36
85	Anti-dsDNA antibody testing by Farr and ELISA techniques is not equivalent. <i>Journal of Rheumatology</i> , 2006, 33, 1785-8.	2.0	36
86	Mycophenolate Mofetil in Nonrenal Manifestations of Systemic Lupus Erythematosus: An Observational Cohort Study. <i>Journal of Rheumatology</i> , 2016, 43, 552-558.	2.0	35
87	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1333-1339.	0.9	35
88	Atherosclerosis and systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , 2000, 2, 19-23.	4.7	34
89	Epidemiology of atherosclerosis in systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , 2009, 11, 248-254.	4.7	34
90	Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2020, 47, 72-81.	2.0	34

#	ARTICLE	IF	CITATIONS
91	A novel lupus activity index accounting for glucocorticoids: SLEDAI-2K glucocorticoid index. <i>Rheumatology</i> , 2018, 57, 1370-1376.	1.9	31
92	Clinical Remission and Low Disease Activity Outcomes Over 10 Years in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2019, 71, 822-828.	3.4	31
93	Antimalarial-induced Cardiomyopathy in Systemic Lupus Erythematosus: As Rare as Considered?. <i>Journal of Rheumatology</i> , 2019, 46, 391-396.	2.0	31
94	Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1.1-2.	0.9	31
95	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. <i>Lupus Science and Medicine</i> , 2021, 8, e000590.	2.7	31
96	Asymptomatic spondylodiscitis an unusual feature of ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 1974, 17, 487-493.	6.7	30
97	Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. II. Predictive factors for perfusion abnormalities. <i>Journal of Rheumatology</i> , 2003, 30, 288-91.	2.0	30
98	Hospitalizations in Patients with Systemic Lupus Erythematosus in an Academic Health Science Center. <i>Journal of Rheumatology</i> , 2017, 44, 1173-1178.	2.0	29
99	<sup>67</sup> Gallium lung scans in progressive systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1983, 26, 969-974.	6.7	28
100	Accelerated nodulosis during azathioprine therapy. <i>Arthritis and Rheumatism</i> , 1991, 34, 123-124.	6.7	28
101	American College of Rheumatology Criteria at Inception, and Accrual over 5 Years in the SLICC Inception Cohort. <i>Journal of Rheumatology</i> , 2014, 41, 875-880.	2.0	28
102	Systemic lupus erythematosus and pulmonary arterial hypertension: links, risks, and management strategies. <i>Open Access Rheumatology: Research and Reviews</i> , 2017, Volume 9, 1-9.	1.6	28
103	Effect of Disease Activity on Organ Damage Progression in Systemic Lupus Erythematosus: University of Toronto Lupus Clinic Cohort. <i>Journal of Rheumatology</i> , 2021, 48, 67-73.	2.0	28
104	Anti-dsDNA and Antichromatin Antibody Isotypes in Serologically Active Clinically Quiescent Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2015, 42, 810-816.	2.0	27
105	Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2018, 45, 393-396.	2.0	27
106	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2020, 106, 102340.	6.5	27
107	The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2021, 23, 29.	3.5	27
108	Autoantibody response to adjuvant and nonadjuvant H1N1 vaccination in systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2011, 63, 1517-1520.	3.4	26

#	ARTICLE	IF	CITATIONS
109	Psoriasis in systemic lupus erythematosus: a single-center experience. <i>Clinical Rheumatology</i> , 2017, 36, 879-884.	2.2	26
110	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. <i>Arthritis and Rheumatology</i> , 2020, 72, 658-666.	5.6	26
111	Association between serum total cholesterol level and renal outcome in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2006, 54, 2211-2219.	6.7	25
112	Comparison of three anti-dsDNA assays: Performance and correlation with systemic lupus erythematosus disease activity. <i>Clinical Biochemistry</i> , 2013, 46, 317-320.	1.9	25
113	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1297-1307.	5.6	25
114	Impact of the new American College of Cardiology/American Heart Association definition of hypertension on atherosclerotic vascular events in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 612-617.	0.9	25
115	Variability over time and correlates of cholesterol and blood pressure in systemic lupus erythematosus: a longitudinal cohort study. <i>Arthritis Research and Therapy</i> , 2010, 12, R125.	3.5	24
116	Summarizing disease features over time: II. Variability measures of SLEDAI-2K. <i>Journal of Rheumatology</i> , 2007, 34, 336-40.	2.0	24
117	Systemic lupus erythematosus: an update on current pharmacotherapy and future directions. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 723-737.	3.1	23
118	Costs Associated With Severe and Nonsevere Systemic Lupus Erythematosus in Canada. <i>Arthritis Care and Research</i> , 2015, 67, 431-436.	3.4	23
119	How can we define low disease activity in systemic lupus erythematosus?. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 1035-1040.	3.4	23
120	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2020, 72, 1800-1808.	3.4	23
121	Ability of non-fasting and fasting triglycerides to predict coronary artery disease in lupus patients. <i>Rheumatology</i> , 2012, 51, 528-534.	1.9	22
122	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. <i>Arthritis Care and Research</i> , 2021, 73, 1231-1235.	3.4	22
123	Gradual Glucocorticosteroid Withdrawal Is Safe in Clinically Quiescent Systemic Lupus Erythematosus. <i>ACR Open Rheumatology</i> , 2021, 3, 550-557.	2.1	22
124	Recommendations for Frequency of Visits to Monitor Systemic Lupus Erythematosus in Asymptomatic Patients: Data from an Observational Cohort Study. <i>Journal of Rheumatology</i> , 2013, 40, 630-633.	2.0	21
125	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2018, 70, 1294-1302.	3.4	21
126	More Consistent Antimalarial Intake in First 5 Years of Disease Is Associated with Better Prognosis in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2018, 45, 90-94.	2.0	20



#	ARTICLE	IF	CITATIONS
127	New EULAR/ACR 2019 SLE Classification Criteria: defining omniosity in SLE. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 767-774.	0.9	20
128	Isolated Hematuria and Sterile Pyuria May Indicate Systemic Lupus Erythematosus Activity. <i>Journal of Rheumatology</i> , 2015, 42, 437-440.	2.0	19
129	Utility of untimed single urine protein/creatinine ratio as a substitute for 24-h proteinuria for assessment of proteinuria in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2015, 17, 296.	3.5	18
130	Lack of Interferon and Proinflammatory Cyto/chemokines in Serologically Active Clinically Quiescent Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2015, 42, 2318-2326.	2.0	18
131	Hydroxychloroquine-Induced Cardiomyopathy in Systemic Lupus Erythematosus. <i>Journal of Clinical Rheumatology</i> , 2016, 22, 287-288.	0.9	18
132	Abnormal Cardiac Biomarkers in Patients with Systemic Lupus Erythematosus and No Prior Heart Disease: A Consequence of Antimalarials?. <i>Journal of Rheumatology</i> , 2019, 46, 64-69.	2.0	18
133	Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2021, 8, e000448.	2.7	18
134	Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria. <i>Lupus Science and Medicine</i> , 2022, 9, e000634.	2.7	18
135	Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data. <i>Lupus Science and Medicine</i> , 2022, 9, e000651.	2.7	18
136	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. <i>Arthritis and Rheumatology</i> , 2020, 72, 1734-1740.	5.6	17
137	Optimal Frequency of Visits for Patients with Systemic Lupus Erythematosus to Measure Disease Activity Over Time. <i>Journal of Rheumatology</i> , 2011, 38, 60-63.	2.0	16
138	Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index. <i>Rheumatology</i> , 2018, 57, 125-133.	1.9	15
139	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. <i>Journal of Rheumatology</i> , 2019, 46, 492-500.	2.0	15
140	High-sensitivity C-reactive protein as a marker of cardiovascular risk in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 3052-3053.	6.7	14
141	Switching Treatment Between Mycophenolate Mofetil and Azathioprine in Lupus Patients: Indications and Outcomes. <i>Arthritis Care and Research</i> , 2014, 66, 1905-1909.	3.4	14
142	Disease Outcomes in Glucocorticosteroid-Naive Patients With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2017, 69, 252-256.	3.4	14
143	Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. <i>Rheumatology</i> , 2021, 60, 4737-4747.	1.9	14
144	Kidney Biopsy in SLE. I. A Clinical-Morphologic Evaluation. <i>QJM - Monthly Journal of the Association of Physicians</i> , 1989, , .	0.5	13

#	ARTICLE	IF	CITATIONS
145	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. <i>Arthritis Care and Research</i> , 2021, 73, 1789-1795.	3.4	13
146	Barriers to medication adherence and degree of nonadherence in a systemic lupus erythematosus (SLE) outpatient population. <i>Rheumatology International</i> , 2021, 41, 1457-1464.	3.0	13
147	Identifying a Response for the Systemic Lupus Erythematosus Disease Activity 2000 Glucocorticoid Index. <i>Arthritis Care and Research</i> , 2021, 73, 1243-1249.	3.4	13
148	Atherosclerotic Vascular Events in Systemic Lupus Erythematosus: An Evolving Story. <i>Journal of Rheumatology</i> , 2020, 47, 66-71.	2.0	13
149	Role of specialty care in the management of patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2002, 29, 1207-10.	2.0	13
150	Outcomes in patients with active lupus nephritis requiring immunosuppressives who never received cyclophosphamide. <i>Journal of Rheumatology</i> , 2007, 34, 1491-6.	2.0	13
151	Systemic Lupus Erythematosus and Diffuse Soft Tissue Calcifications. <i>International Journal of Dermatology</i> , 1983, 22, 416-418.	1.0	12
152	Does Renin-Angiotensin System Blockade Protect Lupus Nephritis Patients From Atherosclerotic Cardiovascular Events? A Case-Control Study. <i>Arthritis Care and Research</i> , 2016, 68, 1497-1504.	3.4	12
153	Practice Variations in the Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus in Canada. <i>Journal of Rheumatology</i> , 2018, 45, 1440-1447.	2.0	12
154	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1010-1012.	0.9	12
155	Studies into the occurrence of soluble antigen-antibody complexes in disease. <i>Arthritis and Rheumatism</i> , 1973, 16, 225-230.	6.7	11
156	Mixed leukocyte reaction in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1976, 19, 532-538.	6.7	11
157	Comparative analysis of long-term organ damage in patients with systemic lupus erythematosus using belimumab versus standard therapy: a post hoc longitudinal study. <i>Lupus Science and Medicine</i> , 2020, 7, e000412.	2.7	11
158	Prevalence and associated factors of resting electrocardiogram abnormalities among systemic lupus erythematosus patients without cardiovascular disease. <i>Arthritis Research and Therapy</i> , 2017, 19, 31.	3.5	10
159	Monophasic Disease Course in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2018, 45, 1131-1135.	2.0	10
160	The SLICC inception cohort for atherosclerosis. <i>Current Rheumatology Reports</i> , 2008, 10, 281-285.	4.7	9
161	Comparison of systemic lupus erythematosus (SLE) patients managed early after diagnosis in specialty versus community care clinics. <i>Clinical Rheumatology</i> , 2017, 36, 1773-1778.	2.2	9
162	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI). <i>Arthritis Care and Research</i> , 2020, , .	3.4	9

#	ARTICLE	IF	CITATIONS
163	Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1143-1150.	0.9	9
164	Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2022, 74, 1822-1828.	3.4	9
165	Should all patients with systemic lupus erythematosus receive cardioprotection with statins?. <i>Nature Clinical Practice Rheumatology</i> , 2007, 3, 536-537.	3.2	8
166	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. <i>Rheumatology</i> , 2019, 58, 1259-1267.	1.9	8
167	Advanced Chronic Kidney Disease in Lupus Nephritis: Is Dialysis Inevitable?. <i>Journal of Rheumatology</i> , 2020, 47, 1366-1373.	2.0	8
168	Immunoglobulin levels in systemic lupus erythematosus: A narrative review. <i>Lupus</i> , 2021, 30, 867-875.	1.6	8
169	THE CLINICAL SIGNIFICANCE OF IMMUNE COMPLEXES IN RHEUMATOID DISEASE. <i>Annals of the New York Academy of Sciences</i> , 1975, 256, 338-341.	3.8	7
170	Outcome measures in systemic lupus erythematosus. <i>Indian Journal of Rheumatology</i> , 2013, 8, S46-S53.	0.4	7
171	SLEDAI-2K Does Not Conceal Worsening in a Particular System When There Is Overall Improvement. <i>Journal of Rheumatology</i> , 2015, 42, 1401-1405.	2.0	7
172	The utility of lupus serology in predicting outcomes of renal transplantation in lupus patients: Systematic literature review and analysis of the Toronto lupus cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 791-797.	3.4	7
173	Acquired low immunoglobulin levels and risk of clinically relevant infection in adult patients with systemic lupus erythematosus: a cohort study. <i>Rheumatology</i> , 2021, 60, 1456-1464.	1.9	7
174	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. <i>Arthritis and Rheumatology</i> , 2021, 73, 2293-2302.	5.6	7
175	Evaluating the Construct of Damage in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2023, 75, 998-1006.	3.4	7
176	Propensity Score Methods in Rare Disease: A Demonstration Using Observational Data in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2021, 48, 321-325.	2.0	6
177	Factors Associated With Rapid Progression to Endstage Kidney Disease in Lupus Nephritis. <i>Journal of Rheumatology</i> , 2021, 48, 228-231.	2.0	6
178	Medium Versus High Initial Prednisone Dose for Remission Induction in Lupus Nephritis: A Propensity Scoreâ€“Matched Analysis. <i>Arthritis Care and Research</i> , 2022, 74, 1451-1458.	3.4	6
179	Clinical Measures, Metrics, and Indices. , 2013, , 563-581.		5
180	FRIO195â€“EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL (DZP) IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): A RANDOMISED, PLACEBO (PBO)-CONTROLLED STUDY. , 2019, , .		5

#	ARTICLE	IF	CITATIONS
181	Rituximab for Sight-Threatening Lupus-Related Retinal Vasculitis. <i>Journal of Clinical Rheumatology</i> , 2018, 24, 93-94.	0.9	4
182	Systemic Glucocorticoids. , 2016, , 521-531.		3
183	60â€¦Association of systemic lupus erythematosus (SLE) genetic susceptibility loci with lupus nephritis in childhood-onset and adult-onset with SLE. , 2019, , .		3
184	Response to placebo in non-renal, non-neuropsychiatric systemic lupus erythematosus: a systematic review and pooled analysis. <i>Rheumatology</i> , 2021, 60, 73-80.	1.9	3
185	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. <i>Lupus</i> , 2021, 30, 096120332110142.	1.6	3
186	Factors associated with refractory renal disease in patients with systemic lupus erythematosus: The role of patient nonadherence. <i>Arthritis and Rheumatism</i> , 2000, 13, 406-408.	6.7	3
187	Outcomes following antimalarial withdrawal in patients with quiescent systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 55, 152046.	3.4	2
188	In Memoriam â€“ Hugh A. Smythe, 1927â€“2012. <i>Journal of Rheumatology</i> , 2013, 40, 343-347.	2.0	1
189	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. <i>Arthritis Research and Therapy</i> , 2017, 19, 287.	3.5	1
190	Dr. Tselios, <i>et al</i> reply. <i>Journal of Rheumatology</i> , 2016, 43, 1767-1767.	2.0	0
191	Reply. <i>Arthritis Care and Research</i> , 2017, 69, 1934-1934.	3.4	0
192	CS-07â€¦Economic evaluation of damage accrual in an international SLE inception cohort. , 2018, , .		0
193	CS-36â€¦Recommendations for the assessment of systemic lupus erythematosus in canada. , 2018, , .		0
194	Dr. Tselios, et al, reply. <i>Journal of Rheumatology</i> , 2019, 46, 1422.2-1422.	2.0	0
195	140â€¦Effect of lupus nephritis on pregnancy outcomes in systemic lupus erythematosus: an individual participant meta-analysis. , 2019, , .		0
196	291â€¦Assessment of the QRISK2, QRISK3, SLE cardiovascular risk equation, modified framingham and framingham risk calculators as predictors of cardiovascular disease events in systemic lupus erythematosus. , 2019, , .		0
197	THU0688â€¦ASSESSMENT OF THE QRISK2, QRISK3, SLE CARDIOVASCULAR RISK EQUATION, FRAMINGHAM AND MODIFIED FRAMINGHAM RISK CALCULATORS AS PREDICTORS OF CARDIOVASCULAR DISEASE EVENTS IN SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		0
198	OPO252â€¦NEUROPATHIES IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM AN INTERNATIONAL, INCEPTION COHORT STUDY. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
199	THU0250â€¦EARLY IMPROVEMENT IN SLEDAI-2K RESPONDER INDEX-50 PREDICTS SRI-4 RESPONSE IN A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF USTEKINUMAB (UST) IN SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		0
200	10â€¦Performance of SLEDAI-2K Responder Index-50 in a Randomized Placebo-Controlled Trial with Ustekinumab (UST) in Systemic Lupus Erythematosus. , 2019, , .		0
201	Differential Diagnosis and Disease Associations. , 2019, , 598-605.		0
202	O8â€¦Performance of the EULAR/ACR 2019 classification criteria for systemic lupus erythematosus in men, ethnicities, and early disease. , 2020, , .		0
203	Systemic glucocorticoids. , 2021, , 597-609.		0
204	Response to: Correspondence on â€œNew EULAR/ACR 2019 SLE classification criteria: defining ominosity in SLEâ€•by Whittall Garcia et al. Annals of the Rheumatic Diseases, 2021, , annrheumdis-2021-221014.	0.9	0
205	56â€¦Self-reported indirect costs are underestimated in a canadian cohort of patients with SLE. , 2019, , .		0
206	1501â€¦Genetics of age at systemic lupus erythematosus diagnosis. , 2021, , .		0
207	1124â€¦Economic evaluation of neuropsychiatric (NP) lupus in an international inception cohort using a multistate model approach. , 2021, , .		0
208	1107â€¦Economic evaluation of hydroxychloroquine use in an international inception cohort. , 2021, , .		0
209	1704â€¦Identifying clusters of longitudinal autoantibody profiles associated with systemic lupus erythematosus disease outcomes. , 2021, , .		0